DongKoo Bio & Pharma Co., Ltd. (KOSDAQ: 006620)

Market Cap	138.15B
Revenue (ttm)	253.71B
Net Income (ttm)	15.34B
Shares Out	27.30M
EPS (ttm)	558.81
PE Ratio	9.06
Forward PE	n/a
Dividend	120.00 (2.34%)
Ex-Dividend Date	Dec 27, 2023

Volume	44,158
Average Volume	213,132
Open	5,090.00
Previous Close	5,060.00
Day's Range	5,040.00 - 5,100.00
52-Week Range	4,300.00 - 8,990.00
Beta	0.70
RSI	47.64
Earnings Date	Mar 19, 2025

About DongKoo Bio & Pharma

DongKoo Bio & Pharma Co., Ltd. manufactures and sells pharmaceuticals in South Korea. The company provides prescription drugs, such as antihistamines, dermatological oral medications, ophthalmic solutions, skeletal muscle relaxants, anti-inflammatory enzymes, antivirals, antibacterial agents, and for the treatment of allergies, liver diseases, mental illnesses, obesity, brain nervous, and endocrine systems; over-the-counter medicines, such as dermatological external preparations, antifungal agents, active probiotic intestinal supplements, antip...

• Industry: Pharmaceutical Preparations
• Founded: 1970
• Employees: 381
• Stock Exchange: KOSDAQ
• Ticker Symbol: 006620

Financial Performance

In 2023, DongKoo Bio & Pharma's revenue was 215.69 billion, an increase of 10.62% compared to the previous year's 194.99 billion. Earnings were 11.81 billion, an increase of 78.59%.